Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos (t) ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomized, open-label, non-inferiority trial
FI: 22,433
Type: Article
Collaboration
Year: 2015
Writers
Perez-Molina, JA; Rubio, R; Rivero, A; Pasquau, J; Suarez-Lozano, I; Riera, M; Estebanez, M; Santos, J; Sanz-Moreno, J; Troy, J; Marino, A; Antela, A; Navarro, J; Esteban, H; Moreno, S
Magazine
Title: LANCET INFECTIOUS DISEASES
Quartile
- D1